{"gene":"CYP2C9","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2001,"finding":"Transcriptional regulation of CYP2C9 by glucocorticoid receptor (GR) and constitutive androstane receptor (CAR): a glucocorticoid-responsive imperfect palindrome was identified at -1662/-1676 and a DR4 motif at -1803/-1818 in the CYP2C9 promoter. The DR4 motif is recognized and transactivated by CAR and pregnane X receptor (PXR). These elements were characterized by deletional analysis, co-transfection experiments, directed mutagenesis, gel shift assays, and response to specific antagonists (RU486, androstanol).","method":"Promoter deletion analysis, site-directed mutagenesis, co-transfection in hepatocytes, electrophoretic mobility shift assay (EMSA), specific receptor antagonists","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (EMSA, mutagenesis, reporter assays, antagonist treatments) in a single rigorous study with functional validation","pmids":["11679585"],"is_preprint":false},{"year":2002,"finding":"Vitamin D receptor (VDR) binds and transactivates xenobiotic-responsive elements (ER6, DR3, DR4) in the CYP2C9 promoter previously identified as PXR/CAR targets, inducing CYP2C9 expression in primary human hepatocytes. VDR, PXR, and CAR compete for the same response elements in the CYP3A4/CYP2C9 promoter region.","method":"EMSA, co-transfection in HepG2 cells using wild-type and mutated oligonucleotides, reporter-gene assays in primary human hepatocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — EMSA plus mutagenesis plus co-transfection with multiple nuclear receptor expression vectors, confirmed in primary hepatocytes","pmids":["11991950"],"is_preprint":false},{"year":1993,"finding":"Structural characterization of the CYP2C9 gene: nine coding exons spanning ~55 kb, with intron-exon organization similar to other CYP2C subfamily members. The 5'-upstream region contains TATA boxes, multiple glucocorticoid regulatory element consensus sequences, and a 15-base sequence with homology to a barbiturate-inducible element from P450BM-3 in Bacillus megaterium.","method":"Genomic cloning, restriction mapping, DNA sequencing of 2200 bp upstream region","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic sequencing and structural analysis, single lab, sequence-based functional inference","pmids":["8333835"],"is_preprint":false},{"year":2000,"finding":"The CYP2C9*3 allele (Ile359Leu substitution) significantly reduces catalytic activity for all seven CYP2C9 substrates tested (S-warfarin, diclofenac, tolbutamide, phenytoin, piroxicam, and others). The Leu359 variant shows higher Km values for all substrates and reduced Vmax/Km (intrinsic clearance) ranging from 3.4- to 26.9-fold lower than wild-type. The substitution also decreases enantiomeric selectivity for phenytoin hydroxylation.","method":"Site-directed mutagenesis, cDNA expression in yeast, enzyme kinetic assays with seven substrates","journal":"Pharmacogenetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-directed mutagenesis combined with heterologous expression and kinetic analysis across seven substrates in a single rigorous study","pmids":["10761997"],"is_preprint":false},{"year":2001,"finding":"CYP2C9*5 variant (Asp360Glu substitution) was identified in African Americans and expressed in insect cells. Comparative kinetic studies showed that Asp360Glu primarily increases Km (12-fold for S-warfarin 7-hydroxylation, 5-fold for diclofenac 4'-hydroxylation, 3-fold for lauric acid ω-1 hydroxylation) relative to wild-type CYP2C9*1, with in vitro intrinsic clearances 8–18% of CYP2C9*1 values.","method":"Single-strand conformational polymorphism, RFLP, baculovirus expression, purification from insect cells, comparative kinetic studies with three substrates","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — purified recombinant protein, enzyme kinetics with multiple substrates, mutagenesis-equivalent allele expression system","pmids":["11455026"],"is_preprint":false},{"year":1997,"finding":"CYP2C9*3 (homozygous) is associated with severely diminished clearance of S-warfarin. A patient homozygous for CYP2C9*3 who could tolerate only 0.5 mg/day warfarin showed a plasma S:R warfarin ratio of 3.9:1 (versus 0.50 ± 0.25 in controls), indicating selective impairment of S-warfarin metabolism. Urinary 7-hydroxywarfarin S:R ratio was normal (4:1), suggesting the defect is in clearance not in stereospecificity of available enzyme.","method":"PCR genotyping, restriction digest, chiral-phase HPLC measurement of plasma warfarin enantiomers and urinary metabolites","journal":"Pharmacogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single patient case with genotype confirmation and pharmacokinetic profiling, mechanistically informative but single subject","pmids":["9352571"],"is_preprint":false},{"year":2010,"finding":"CYP2C9 and CYP3A4 physically interact via their hydrophobic N-terminal membrane-anchoring domains to form a heteromeric complex. This interaction inhibits CYP2C9-mediated metabolism (up to 80% inhibition of S-naproxen and S-flurbiprofen hydroxylation) without changing Km values, while CYP2C9 does not alter CYP3A4 testosterone metabolism. Truncation of either enzyme's N-terminus abolishes the inhibition. Increasing CPR concentrations relieves the inhibition.","method":"Reconstituted system incubations, truncated protein constructs, co-immunoprecipitation, varied CPR and cytochrome b5 concentrations","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — co-IP confirmed physical interaction, reconstituted system with domain truncation mutagenesis and activity assays, multiple orthogonal approaches","pmids":["20215413"],"is_preprint":false},{"year":2014,"finding":"Modulation of CYP3A4 protein levels in human hepatocytes (HepatoPac long-term culture) inversely affects CYP2C9 activity: siRNA-mediated CYP3A4 knockdown (60% decrease) caused a 74% increase in CYP2C9 activity with no change in CYP2C9 mRNA, confirming post-translational protein-protein interaction between CYP3A4 and CYP2C9 in a physiological in vitro system.","method":"siRNA knockdown of CYP3A4 in HepatoPac long-term human hepatocyte culture, activity assays, mRNA and protein quantification","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockdown with functional readout in physiologically relevant system, single lab, confirms prior recombinant system finding","pmids":["25157098"],"is_preprint":false},{"year":2015,"finding":"miR-130b directly targets the CYP2C9 3'-UTR and negatively regulates CYP2C9 activity. Transfection of miR-130b mimics in HepaRG cells significantly reduced CYP2C9 mRNA expression and decreased CYP2C9 enzyme activity by at least 30%. miR-130b also indirectly downregulates CYP2C9 by suppressing nuclear receptors CAR and FXRα. miR-130b levels are elevated in cholestasis and inflammation.","method":"miRNA mimic transfection in HepaRG cells, quantitative RT-PCR, LC-MS/MS cocktail P450 activity assay, 3'-UTR reporter gene assay","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter gene assay confirmed direct 3'-UTR targeting; functional activity reduction confirmed; single lab, two orthogonal methods","pmids":["25802328"],"is_preprint":false},{"year":2011,"finding":"Estrogen receptor α (ERα) regulates CYP2C9 transcription through a functionally relevant ERE half-site at position -149/-145 in the CYP2C9 promoter. ERα binds this site (confirmed by EMSA and antibody supershift). ERα ligands differentially regulate CYP2C9 promoter activity: 4-hydroxytamoxifen and raloxifene upregulate, while 17α-ethinylestradiol suppresses, CYP2C9 promoter activity. Mutations in the ERE half-site abolish these effects. ChIP confirmed ERα association with the CYP2C9 promoter in cells.","method":"Luciferase reporter assay, site-directed mutagenesis of ERE half-site, EMSA with antibody supershift, chromatin immunoprecipitation (ChIP), primary hepatocyte experiments","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (reporter assay, mutagenesis, EMSA, supershift, ChIP, primary hepatocytes) in single rigorous study","pmids":["21493749"],"is_preprint":false},{"year":2006,"finding":"PXR and CAR activate CYP2C9 gene expression in mouse liver through elements residing in the -2000 to -1000 bp region of the 5'-flanking sequence. Chemical inducers of PXR (rifampicin, PCN) and CAR (phenobarbital, TCPOBOP) significantly enhanced CYP2C9 promoter-driven luciferase expression when cotransfected with respective receptor expression vectors in vivo in mouse liver.","method":"Hydrodynamic delivery of reporter constructs to mouse liver, co-transfection with PXR or CAR expression vectors, luciferase reporter assay","journal":"Molecular pharmaceutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo reporter assay with receptor co-expression, single lab, consistent with prior in vitro findings","pmids":["16749864"],"is_preprint":false},{"year":2009,"finding":"Active-site mutagenesis at Phe100, Phe114, Leu208, and Phe476 in CYP2C9 reveals substrate-specific binding locations: F100L and F114W mutants show 4-5-fold increased catalytic efficiency for phenytoin, while F100W, F114L, F476L, and F476W mutants lose >90% phenytoin hydroxylation capacity. The pattern differs from S-warfarin and S-flurbiprofen, indicating these substrates occupy discrete locations within the active site. L208V and F114L mutants alter phenytoin's catalytic orientation. L208V uniquely enhances 6-hydroxylation of S-warfarin, providing experimental evidence for the F-G loop region in dictating substrate orientation.","method":"Site-directed mutagenesis of nine active-site positions, in vitro kinetic analysis, stereochemical analysis of hydroxylated metabolites","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic site-directed mutagenesis of nine positions with kinetic and stereochemical readouts, multiple substrates compared","pmids":["19258521"],"is_preprint":false},{"year":2013,"finding":"Functional characterization of 32 CYP2C9 allelic variants expressed in COS-7 cells using S-warfarin as substrate revealed that CYP2C9.18, .21, .24, .26, .33, and .35 exhibit no enzyme activity, and 12 additional variants show significantly decreased activity, establishing the molecular basis for loss-of-function alleles.","method":"Transient expression of variant CYP2C9 proteins in COS-7 cells, S-warfarin hydroxylation kinetic assay","journal":"The pharmacogenomics journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — heterologous expression with functional enzyme assay, single lab, broad allele coverage","pmids":["23752738"],"is_preprint":false},{"year":2021,"finding":"Massively parallel activity profiling of 6,142 CYP2C9 missense variants using a pooled yeast-based click-seq assay, combined with VAMP-seq abundance measurement in human cells for 6,370 variants, revealed that almost two-thirds of CYP2C9 variants show decreased activity and that protein abundance (stability) accounts for approximately half of the variation in CYP2C9 function.","method":"Click-seq pooled yeast activity assay, VAMP-seq (variant abundance by massively parallel sequencing) in human cells","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — massively parallel functional assay with orthogonal abundance measurement, thousands of variants assessed, rigorous quantitative framework","pmids":["34314704"],"is_preprint":false},{"year":2018,"finding":"CYP2C9 metabolizes arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), and the CYP2C9*2 and CYP2C9*3 variants metabolize AA less efficiently than CYP2C9*1, primarily due to impaired reduction of these variant proteins by NADPH-P450 reductase. Expression of CYP2C9*2 or *3 in NSCLC cells produced lower EET levels, smaller/less vascularized tumors in mice, and reduced endothelial cell proliferation and migration, establishing a direct mechanistic link between CYP2C9 variant activity, EET biosynthesis, and tumor angiogenesis.","method":"In vitro kinetic assays with purified CYP2C9*1, *2, *3 proteins, NADPH-P450 reductase activity assays, NSCLC cell tumor xenograft mouse model, endothelial cell proliferation/migration assays, EET quantification","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — purified protein kinetics plus mechanistic in vivo tumor model plus cell biology assays, multiple orthogonal methods","pmids":["30012669"],"is_preprint":false},{"year":2001,"finding":"CYP2C9 is the major enzyme responsible for losartan oxidation to the active carboxylic acid metabolite E-3174. CYP2C9 inhibitor sulfaphenazole blocked E-3174 formation at low losartan concentrations, while CYP3A4 inhibitor triacetyloleandomycin was effective only at high concentrations. CYP2C9.2 and CYP2C9.3 yeast-expressed variants showed significantly reduced losartan oxidation, primarily due to lower Vmax. CYP2C9*3 liver microsomes also showed lower oxidation rates.","method":"Human liver microsome incubations with selective inhibitors, yeast expression of CYP2C9 variants, HPLC metabolite analysis, kinetic analysis across 25 individual liver microsome samples with genotype correlation","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — selective inhibitor in microsomes plus heterologous expression of variants plus individual human liver microsome panel, multiple orthogonal approaches","pmids":["11408373"],"is_preprint":false},{"year":2005,"finding":"CYP2C9*13 (Leu90Pro substitution) reduces lornoxicam 5'-hydroxylation in COS-7 cells (Vmax/Km 12% of wild-type CYP2C9*1; compared to 28% for CYP2C9*3). Protein levels of both CYP2C9*3 and *13 were lower than CYP2C9*1. In a clinical study, CYP2C9*1/*13 subjects showed 1.9-fold higher lornoxicam AUC and 44% lower oral clearance versus CYP2C9*1/*1.","method":"Transient transfection expression in COS-7 cells, enzyme kinetic assays, clinical pharmacokinetic study in CYP2C9*1/*13 heterozygotes","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinetics with heterologous expression corroborated by clinical PK data, single lab","pmids":["15764711"],"is_preprint":false},{"year":2018,"finding":"Dicloxacillin induces CYP2C9 expression and activity through activation of pregnane X receptor (PXR): dicloxacillin treatment in primary human hepatocytes produced a statistically significant dose-dependent increase in CYP2C9 expression and activity, and luciferase assays confirmed PXR activation as the mechanism.","method":"Open-label randomized clinical crossover study with tolbutamide as CYP2C9 probe, primary human hepatocyte gene expression and activity assays, luciferase-based nuclear receptor activation assay","journal":"British journal of clinical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clinical PK data plus mechanistic hepatocyte and reporter assay experiments, single lab","pmids":["29105855"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of CYP2C9 in complex with a TCA1 antitubercular thiophene analog revealed interaction patterns within the CYP2C9 active site; structure-guided optimization enabled generation of molecules with differential inhibitory activities against DprE1 and CYP2C9, providing structural basis for CYP2C9 inhibitor selectivity.","method":"X-ray crystallography of CYP2C9 in complex with TCA1 analog, structure-guided analog synthesis","journal":"Angewandte Chemie (International ed. in English)","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure obtained but reported as secondary finding in a TB drug development paper; single study, no mutagenesis validation of binding mode","pmids":["28815830"],"is_preprint":false},{"year":2023,"finding":"Heat stress increases CYP2C9 expression and EET production in porcine Sertoli cells, activating the Ras-JNK signaling pathway and inducing ferroptosis. Pharmacological inhibition of CYP2C9 with sulfaphenazole or siRNA knockdown of CYP2C9 reduced EET content, suppressed Ras-JNK activation, and alleviated ferroptosis. Ras inhibitor (salirasib) did not affect CYP2C9 expression or EET levels, indicating unidirectional signaling from CYP2C9-EETs to Ras-JNK.","method":"CYP2C9 siRNA knockdown, sulfaphenazole pharmacological inhibition, Ras inhibitor, flow cytometry (apoptosis/ROS), Western blotting (GPX4, TFR1, Ferritin, p-JNK), EET quantification in porcine Sertoli cells","journal":"Theriogenology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus pharmacological inhibition plus genetic pathway dissection (Ras inhibitor), single lab, porcine model","pmids":["38103405"],"is_preprint":false},{"year":2010,"finding":"CYP2C9 promotes esophageal cancer cell proliferation through EET production. Selective pharmacological inhibition of CYP2C9 decreased tumor cell proliferation in esophageal cancer cell lines (KYSE30, PT1590, OE19), and this anti-proliferative effect was reversed by exogenous addition of 11,12-EET. CYP2C9 inhibition caused G0/G1 cell-cycle arrest.","method":"CYP2C9 inhibitor treatment of cancer cell lines, cell cycle analysis by FACS, EET rescue experiment","journal":"Prostaglandins & other lipid mediators","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with substrate rescue, cell cycle analysis, single lab","pmids":["21167292"],"is_preprint":false},{"year":2004,"finding":"Active-site probing with hydantoin and barbiturate inhibitors established that CYP2C9 active site differs from CYP2C19 in stereochemical requirements: inhibitor stereochemistry does not markedly influence Ki toward CYP2C9, and log P adequately predicts inhibitor potency for CYP2C9, contrasting with CYP2C19 where stereochemistry is a major factor. All tested compounds were competitive inhibitors of CYP2C9.","method":"Synthesis of N-3 alkyl-substituted phenytoin, nirvanol, and barbiturate derivatives; Ki determination against recombinant CYP2C9 and CYP2C19; CoMFA modeling","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — systematic SAR with recombinant enzyme kinetics and computational modeling, single lab","pmids":["15288804"],"is_preprint":false},{"year":2010,"finding":"CYP2C9*3 (Ile359Leu) and CYP2C9*13 (Leu90Pro) variants reduce diclofenac 4'-hydroxylation in yeast-expressed enzyme. Both variants also alter the inhibitory potency of clinical drugs against diclofenac metabolism; in particular, CYP2C9*13 significantly weakens inhibition by sulfaphenazole, fluvastatin, fluvoxamine, and tranylcypromine, demonstrating that active-site substitutions alter drug-drug interaction profiles.","method":"Yeast expression of CYP2C9*1, *3, *13, kinetic analysis of diclofenac 4'-hydroxylation, Ki determination for nine inhibitors against each variant","journal":"Drug metabolism and pharmacokinetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — heterologous expression with systematic kinetics and inhibition profiling, single lab","pmids":["20814155"],"is_preprint":false}],"current_model":"CYP2C9 is a hepatic cytochrome P450 enzyme that catalyzes the hydroxylation of ~15% of clinically used drugs (including S-warfarin, phenytoin, diclofenac, tolbutamide, losartan, NSAIDs, and sulfonylureas) as well as endogenous arachidonic acid to epoxyeicosatrienoic acids (EETs); its active site accommodates substrates through substrate-specific binding subsites defined by residues Phe100, Phe114, Leu208, and Phe476; common coding variants CYP2C9*2 (Arg144Cys), *3 (Ile359Leu), *5 (Asp360Glu), and *13 (Leu90Pro) reduce intrinsic clearance primarily by increasing Km and, for *3, by impairing reduction by NADPH-P450 reductase; transcription is induced via GR, CAR, PXR, and VDR acting on promoter elements at -1662/-1676 (GRE palindrome), -1803/-1818 (DR4/CAR-PXR element), and by ERα through an ERE half-site at -149/-145, while miR-130b directly suppresses CYP2C9 via its 3'-UTR; CYP2C9 forms a physical heteromeric complex with CYP3A4 through hydrophobic N-terminal membrane anchors, resulting in inhibition of CYP2C9 activity; and CYP2C9-derived EETs promote tumor cell proliferation and angiogenesis through a Ras-JNK signaling axis."},"narrative":{"mechanistic_narrative":"CYP2C9 is a hepatic cytochrome P450 monooxygenase that hydroxylates a broad range of clinical drugs—including S-warfarin, diclofenac, tolbutamide, phenytoin, losartan, and NSAIDs—as well as endogenous arachidonic acid to epoxyeicosatrienoic acids (EETs) [PMID:10761997, PMID:30012669, PMID:11408373]. Substrate handling is governed by discrete active-site subsites: systematic mutagenesis at Phe100, Phe114, Leu208, and Phe476 shows that distinct substrates occupy different binding locations, with the F-G loop region dictating substrate orientation, so that single substitutions can selectively enhance or abolish turnover of one substrate without affecting others [PMID:19258521]. Common coding variants degrade function by mechanistically distinct routes: CYP2C9*3 (Ile359Leu) and *5 (Asp360Glu) raise Km and lower intrinsic clearance across multiple substrates [PMID:10761997, PMID:11455026], *13 (Leu90Pro) and *3 reduce protein abundance [PMID:15764711], and *2/*3 specifically impair reduction by NADPH-P450 reductase [PMID:30012669]; massively parallel variant profiling generalizes this, showing that nearly two-thirds of missense variants reduce activity and that protein stability accounts for roughly half of functional variation [PMID:34314704]. Allelic loss-of-function carries direct clinical consequence, as homozygous *3 produces severely diminished S-warfarin clearance [PMID:9352571]. Transcription is controlled by a nuclear-receptor regulatory network: GR, CAR, PXR, and VDR act through promoter elements including a glucocorticoid palindrome at -1662/-1676 and a DR4 motif at -1803/-1818, for which these receptors compete [PMID:11679585, PMID:11991950, PMID:16749864], ERα regulates the gene through an ERE half-site at -149/-145 in a ligand-dependent manner [PMID:21493749], and miR-130b suppresses CYP2C9 both directly via the 3'-UTR and indirectly by repressing CAR and FXRα [PMID:25802328]. Post-translationally, CYP2C9 forms a heteromeric complex with CYP3A4 via their N-terminal membrane anchors, which inhibits CYP2C9 activity in a manner relieved by increasing reductase [PMID:20215413, PMID:25157098]. Beyond xenobiotic metabolism, CYP2C9-derived EETs drive proliferation and angiogenesis in tumor cells through a Ras-JNK signaling axis [PMID:30012669, PMID:21167292, PMID:38103405].","teleology":[{"year":1993,"claim":"Established the genomic architecture and regulatory landscape of CYP2C9, framing where transcriptional control would later be mapped.","evidence":"Genomic cloning and sequencing of the gene and 2200 bp upstream region","pmids":["8333835"],"confidence":"Medium","gaps":["Regulatory elements inferred from sequence homology, not functionally validated","No protein-level functional data"]},{"year":1997,"claim":"Connected a defined CYP2C9 genotype to a clinical metabolic phenotype, showing homozygous *3 selectively impairs S-warfarin clearance.","evidence":"PCR genotyping and chiral-phase HPLC of warfarin enantiomers in a homozygous *3 patient","pmids":["9352571"],"confidence":"Medium","gaps":["Single-subject case","Does not isolate the enzymatic mechanism of impairment"]},{"year":2000,"claim":"Defined the enzymatic basis of the *3 loss-of-function allele as a broad increase in Km/decrease in intrinsic clearance across substrates.","evidence":"Site-directed mutagenesis, yeast cDNA expression, kinetics with seven substrates","pmids":["10761997"],"confidence":"High","gaps":["Does not address protein abundance contribution","Yeast system may not reflect hepatic reductase coupling"]},{"year":2001,"claim":"Identified the nuclear-receptor promoter elements (GR palindrome, DR4 for CAR/PXR) controlling CYP2C9 induction, defining the xenobiotic transcriptional axis.","evidence":"Promoter deletion, mutagenesis, EMSA, co-transfection in hepatocytes with antagonists","pmids":["11679585"],"confidence":"High","gaps":["Endogenous physiological inducers not enumerated","Cross-talk between receptors not resolved here"]},{"year":2001,"claim":"Characterized the *5 variant as another Km-increasing loss-of-function allele and established CYP2C9 as the major losartan-activating enzyme.","evidence":"Baculovirus expression and purification, kinetics; microsome inhibitor studies and variant expression for losartan","pmids":["11455026","11408373"],"confidence":"High","gaps":["Substrate-specific magnitude of *5 effect varies","Reductase coupling not measured"]},{"year":2002,"claim":"Extended the regulatory network by showing VDR competes with PXR/CAR for the same response elements, integrating vitamin D signaling into CYP2C9 control.","evidence":"EMSA, mutated oligonucleotides, reporter assays in HepG2 and primary hepatocytes","pmids":["11991950"],"confidence":"High","gaps":["Physiological relevance of VDR induction in vivo not established","Competition dynamics quantitatively undefined"]},{"year":2006,"claim":"Confirmed PXR/CAR-driven induction operates in intact liver, validating the in vitro promoter model in vivo.","evidence":"Hydrodynamic reporter delivery to mouse liver with receptor co-expression and chemical inducers","pmids":["16749864"],"confidence":"Medium","gaps":["Mouse liver context, not human","Precise element usage not mapped in vivo"]},{"year":2009,"claim":"Resolved the active site into substrate-specific binding subsites, explaining how single residues differentially govern turnover of distinct drugs.","evidence":"Site-directed mutagenesis of nine active-site positions with kinetic and stereochemical readouts","pmids":["19258521"],"confidence":"High","gaps":["No co-crystal structure for most substrates","Does not address dynamics of substrate entry"]},{"year":2010,"claim":"Revealed a post-translational regulatory mechanism: CYP2C9 forms an inhibitory N-terminal-anchored heterocomplex with CYP3A4.","evidence":"Reconstituted system, N-terminal truncation constructs, co-IP, varied CPR/b5","pmids":["20215413"],"confidence":"High","gaps":["Stoichiometry of the complex undefined","Structural basis of the interface not solved"]},{"year":2010,"claim":"Linked CYP2C9-derived EETs to cancer cell proliferation, opening an endogenous signaling role beyond drug metabolism.","evidence":"Pharmacological CYP2C9 inhibition in esophageal cancer lines with cell-cycle analysis and 11,12-EET rescue","pmids":["21167292"],"confidence":"Medium","gaps":["Inhibitor selectivity not genetically confirmed here","Downstream signaling not dissected"]},{"year":2011,"claim":"Added estrogen-receptor control through an ERE half-site, with ligand-dependent up- or down-regulation.","evidence":"Reporter assays, ERE mutagenesis, EMSA/supershift, ChIP, primary hepatocytes","pmids":["21493749"],"confidence":"High","gaps":["Physiological estrogen effect on hepatic CYP2C9 in vivo not quantified","Interaction with xenobiotic receptors unexplored"]},{"year":2013,"claim":"Broadened the catalog of loss-of-function alleles, identifying multiple null and reduced-activity variants on S-warfarin.","evidence":"Transient expression of 32 variants in COS-7 with S-warfarin kinetics","pmids":["23752738"],"confidence":"Medium","gaps":["Single substrate tested","Protein abundance vs catalytic effects not separated"]},{"year":2014,"claim":"Demonstrated the CYP3A4-CYP2C9 interaction operates in physiological hepatocytes, with CYP3A4 levels inversely tuning CYP2C9 activity.","evidence":"CYP3A4 siRNA knockdown in HepatoPac culture with activity, mRNA, and protein readouts","pmids":["25157098"],"confidence":"Medium","gaps":["Endogenous regulators of CYP3A4 abundance not addressed","Quantitative interplay across genotypes unknown"]},{"year":2015,"claim":"Identified miR-130b as a direct and indirect post-transcriptional repressor of CYP2C9, linking expression to cholestasis and inflammation.","evidence":"miRNA mimic transfection in HepaRG, 3'-UTR reporter, qRT-PCR, LC-MS/MS activity","pmids":["25802328"],"confidence":"Medium","gaps":["In vivo regulation by miR-130b not demonstrated","Relative weight of direct vs indirect (CAR/FXRα) effects unclear"]},{"year":2018,"claim":"Established the EET-tumor angiogenesis axis mechanistically and showed reduced-function variants impair it via defective reductase coupling.","evidence":"Purified protein kinetics, reductase assays, NSCLC xenografts, endothelial assays, EET quantification","pmids":["30012669"],"confidence":"High","gaps":["Generalizability across tumor types not shown","Contribution of EETs vs other CYP2C9 products not isolated"]},{"year":2021,"claim":"Provided a genome-scale functional map showing protein stability accounts for about half of CYP2C9 functional variation.","evidence":"Click-seq pooled yeast activity assay plus VAMP-seq abundance in human cells across thousands of variants","pmids":["34314704"],"confidence":"High","gaps":["Single substrate context for activity assay","Clinical translation of variant scores not validated"]},{"year":2023,"claim":"Generalized the CYP2C9-EET-Ras-JNK signaling axis to stress-induced ferroptosis, defining it as unidirectional from enzyme to signaling.","evidence":"siRNA, sulfaphenazole, Ras inhibitor epistasis, ferroptosis markers in porcine Sertoli cells","pmids":["38103405"],"confidence":"Medium","gaps":["Porcine model; human relevance untested","Molecular link between EETs and Ras activation not defined"]},{"year":null,"claim":"How transcriptional, post-transcriptional (miR-130b), and post-translational (CYP3A4 complex) layers are jointly coordinated to set hepatic CYP2C9 activity in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated in vivo model combining the regulatory layers","Structural basis of the CYP3A4 interface unsolved","Relative contribution of each layer to interindividual drug-response variability unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[3,4,14,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,11,14]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[14,20,19]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[3,15,22]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[14,4]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,9,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,20,19]}],"complexes":[],"partners":["CYP3A4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11712","full_name":"Cytochrome P450 2C9","aliases":["(R)-limonene 6-monooxygenase","(S)-limonene 6-monooxygenase","(S)-limonene 7-monooxygenase","CYPIIC9","Cholesterol 25-hydroxylase","Cytochrome P-450MP","Cytochrome P450 MP-4","Cytochrome P450 MP-8","Cytochrome P450 PB-1","S-mephenytoin 4-hydroxylase"],"length_aa":490,"mass_kda":55.6,"function":"A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:15766564, PubMed:19965576, PubMed:7574697, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9435160, PubMed:9866708). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031)","subcellular_location":"Endoplasmic reticulum membrane; Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P11712/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP2C9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP2C9","total_profiled":1310},"omim":[{"mim_id":"608547","title":"VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1; VKORC1","url":"https://www.omim.org/entry/608547"},{"mim_id":"603065","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP I, MEMBER 2; NR1I2","url":"https://www.omim.org/entry/603065"},{"mim_id":"601130","title":"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9","url":"https://www.omim.org/entry/601130"},{"mim_id":"601129","title":"CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 8; CYP2C8","url":"https://www.omim.org/entry/601129"},{"mim_id":"186770","title":"T-CELL LEUKEMIA, HOMEOBOX 1; TLX1","url":"https://www.omim.org/entry/186770"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":1607.6}],"url":"https://www.proteinatlas.org/search/CYP2C9"},"hgnc":{"alias_symbol":["P450IIC9"],"prev_symbol":["CYP2C10"]},"alphafold":{"accession":"P11712","domains":[{"cath_id":"1.10.630.10","chopping":"79-488","consensus_level":"medium","plddt":93.9662,"start":79,"end":488}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11712","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11712-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11712-F1-predicted_aligned_error_v6.png","plddt_mean":92.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP2C9","jax_strain_url":"https://www.jax.org/strain/search?query=CYP2C9"},"sequence":{"accession":"P11712","fasta_url":"https://rest.uniprot.org/uniprotkb/P11712.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11712/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11712"}},"corpus_meta":[{"pmid":"11926893","id":"PMC_11926893","title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.","date":"2002","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/11926893","citation_count":807,"is_preprint":false},{"pmid":"17900275","id":"PMC_17900275","title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.","date":"2007","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/17900275","citation_count":603,"is_preprint":false},{"pmid":"11991950","id":"PMC_11991950","title":"Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11991950","citation_count":288,"is_preprint":false},{"pmid":"12406644","id":"PMC_12406644","title":"CYP2C9 allelic variants: ethnic distribution and functional significance.","date":"2002","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12406644","citation_count":272,"is_preprint":false},{"pmid":"12573484","id":"PMC_12573484","title":"The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12573484","citation_count":267,"is_preprint":false},{"pmid":"12496751","id":"PMC_12496751","title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.","date":"2002","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12496751","citation_count":266,"is_preprint":false},{"pmid":"8946475","id":"PMC_8946475","title":"Genetic analysis of the human cytochrome P450 CYP2C9 locus.","date":"1996","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8946475","citation_count":254,"is_preprint":false},{"pmid":"9352571","id":"PMC_9352571","title":"Genetic association between sensitivity to warfarin and expression of CYP2C9*3.","date":"1997","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9352571","citation_count":253,"is_preprint":false},{"pmid":"14634042","id":"PMC_14634042","title":"Developmental expression of human hepatic CYP2C9 and CYP2C19.","date":"2003","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/14634042","citation_count":236,"is_preprint":false},{"pmid":"10761997","id":"PMC_10761997","title":"CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.","date":"2000","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10761997","citation_count":234,"is_preprint":false},{"pmid":"11679585","id":"PMC_11679585","title":"Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11679585","citation_count":218,"is_preprint":false},{"pmid":"11455026","id":"PMC_11455026","title":"Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11455026","citation_count":214,"is_preprint":false},{"pmid":"15822186","id":"PMC_15822186","title":"Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.","date":"2005","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/15822186","citation_count":185,"is_preprint":false},{"pmid":"15177309","id":"PMC_15177309","title":"Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.","date":"2004","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/15177309","citation_count":165,"is_preprint":false},{"pmid":"29283396","id":"PMC_29283396","title":"Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.","date":"2017","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29283396","citation_count":163,"is_preprint":false},{"pmid":"17161452","id":"PMC_17161452","title":"Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.","date":"2006","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/17161452","citation_count":157,"is_preprint":false},{"pmid":"11875364","id":"PMC_11875364","title":"Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.","date":"2002","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11875364","citation_count":152,"is_preprint":false},{"pmid":"11408373","id":"PMC_11408373","title":"Role of CYP2C9 polymorphism in losartan oxidation.","date":"2001","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/11408373","citation_count":140,"is_preprint":false},{"pmid":"17220242","id":"PMC_17220242","title":"Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.","date":"2007","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/17220242","citation_count":133,"is_preprint":false},{"pmid":"14641553","id":"PMC_14641553","title":"Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.","date":"2003","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/14641553","citation_count":115,"is_preprint":false},{"pmid":"16963489","id":"PMC_16963489","title":"CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.","date":"2006","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/16963489","citation_count":97,"is_preprint":false},{"pmid":"16118328","id":"PMC_16118328","title":"Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/16118328","citation_count":90,"is_preprint":false},{"pmid":"34314704","id":"PMC_34314704","title":"Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34314704","citation_count":85,"is_preprint":false},{"pmid":"12893985","id":"PMC_12893985","title":"Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.","date":"2003","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12893985","citation_count":84,"is_preprint":false},{"pmid":"15776277","id":"PMC_15776277","title":"Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.","date":"2005","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15776277","citation_count":81,"is_preprint":false},{"pmid":"15229460","id":"PMC_15229460","title":"CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.","date":"2004","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15229460","citation_count":72,"is_preprint":false},{"pmid":"23752738","id":"PMC_23752738","title":"Functional characterization of 32 CYP2C9 allelic variants.","date":"2013","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/23752738","citation_count":70,"is_preprint":false},{"pmid":"15260906","id":"PMC_15260906","title":"QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.","date":"2004","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15260906","citation_count":70,"is_preprint":false},{"pmid":"8333835","id":"PMC_8333835","title":"Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8333835","citation_count":68,"is_preprint":false},{"pmid":"15764711","id":"PMC_15764711","title":"Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15764711","citation_count":66,"is_preprint":false},{"pmid":"25802328","id":"PMC_25802328","title":"Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9.","date":"2015","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25802328","citation_count":65,"is_preprint":false},{"pmid":"17849045","id":"PMC_17849045","title":"Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.","date":"2007","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/17849045","citation_count":65,"is_preprint":false},{"pmid":"14726986","id":"PMC_14726986","title":"Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.","date":"2004","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14726986","citation_count":64,"is_preprint":false},{"pmid":"34109627","id":"PMC_34109627","title":"PharmVar GeneFocus: CYP2C9.","date":"2021","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34109627","citation_count":58,"is_preprint":false},{"pmid":"11470765","id":"PMC_11470765","title":"Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.","date":"2001","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11470765","citation_count":56,"is_preprint":false},{"pmid":"15133536","id":"PMC_15133536","title":"The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes.","date":"2004","source":"American journal of therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15133536","citation_count":55,"is_preprint":false},{"pmid":"21447389","id":"PMC_21447389","title":"Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.","date":"2011","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21447389","citation_count":51,"is_preprint":false},{"pmid":"12451434","id":"PMC_12451434","title":"Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations.","date":"2002","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12451434","citation_count":51,"is_preprint":false},{"pmid":"25967074","id":"PMC_25967074","title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children.","date":"2015","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/25967074","citation_count":47,"is_preprint":false},{"pmid":"20215413","id":"PMC_20215413","title":"CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus.","date":"2010","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/20215413","citation_count":45,"is_preprint":false},{"pmid":"23118328","id":"PMC_23118328","title":"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.","date":"2012","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/23118328","citation_count":45,"is_preprint":false},{"pmid":"15197523","id":"PMC_15197523","title":"CYP2C9 genetic variants and losartan oxidation in a Turkish population.","date":"2004","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15197523","citation_count":44,"is_preprint":false},{"pmid":"10584064","id":"PMC_10584064","title":"Homology modeling and substrate binding study of human CYP2C9 enzyme.","date":"1999","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/10584064","citation_count":44,"is_preprint":false},{"pmid":"19381162","id":"PMC_19381162","title":"Global variation in CYP2C8-CYP2C9 functional haplotypes.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19381162","citation_count":44,"is_preprint":false},{"pmid":"21841812","id":"PMC_21841812","title":"Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.","date":"2011","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21841812","citation_count":43,"is_preprint":false},{"pmid":"16928789","id":"PMC_16928789","title":"Enzyme source effects on CYP2C9 kinetics and inhibition.","date":"2006","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/16928789","citation_count":42,"is_preprint":false},{"pmid":"27539372","id":"PMC_27539372","title":"CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.","date":"2016","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27539372","citation_count":42,"is_preprint":false},{"pmid":"23863877","id":"PMC_23863877","title":"Association of CYP2C9*2 with bosentan-induced liver injury.","date":"2013","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23863877","citation_count":42,"is_preprint":false},{"pmid":"30789308","id":"PMC_30789308","title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.","date":"2019","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30789308","citation_count":41,"is_preprint":false},{"pmid":"23041981","id":"PMC_23041981","title":"Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.","date":"2012","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/23041981","citation_count":41,"is_preprint":false},{"pmid":"28815830","id":"PMC_28815830","title":"Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.","date":"2017","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/28815830","citation_count":41,"is_preprint":false},{"pmid":"15592327","id":"PMC_15592327","title":"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.","date":"2004","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15592327","citation_count":39,"is_preprint":false},{"pmid":"19442216","id":"PMC_19442216","title":"Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism.","date":"2009","source":"Medicinal chemistry (Shariqah (United Arab Emirates))","url":"https://pubmed.ncbi.nlm.nih.gov/19442216","citation_count":38,"is_preprint":false},{"pmid":"26037375","id":"PMC_26037375","title":"CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.","date":"2015","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26037375","citation_count":37,"is_preprint":false},{"pmid":"14970873","id":"PMC_14970873","title":"CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14970873","citation_count":35,"is_preprint":false},{"pmid":"16111713","id":"PMC_16111713","title":"Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16111713","citation_count":35,"is_preprint":false},{"pmid":"29119932","id":"PMC_29119932","title":"Relevance of CYP2C9 Function in Valproate Therapy.","date":"2019","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29119932","citation_count":33,"is_preprint":false},{"pmid":"24474498","id":"PMC_24474498","title":"VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.","date":"2014","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24474498","citation_count":33,"is_preprint":false},{"pmid":"32004414","id":"PMC_32004414","title":"CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.","date":"2020","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/32004414","citation_count":32,"is_preprint":false},{"pmid":"29793229","id":"PMC_29793229","title":"The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.","date":"2004","source":"Personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29793229","citation_count":32,"is_preprint":false},{"pmid":"32406758","id":"PMC_32406758","title":"Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions.","date":"2020","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32406758","citation_count":30,"is_preprint":false},{"pmid":"19152219","id":"PMC_19152219","title":"CYP2C9 polymorphisms: considerations in NSAID therapy.","date":"2009","source":"Current opinion in drug discovery & development","url":"https://pubmed.ncbi.nlm.nih.gov/19152219","citation_count":29,"is_preprint":false},{"pmid":"27803446","id":"PMC_27803446","title":"Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.","date":"2016","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/27803446","citation_count":28,"is_preprint":false},{"pmid":"29105855","id":"PMC_29105855","title":"Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.","date":"2018","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29105855","citation_count":27,"is_preprint":false},{"pmid":"19669737","id":"PMC_19669737","title":"CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.","date":"2009","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19669737","citation_count":27,"is_preprint":false},{"pmid":"20602621","id":"PMC_20602621","title":"Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.","date":"2010","source":"Toxicology mechanisms and methods","url":"https://pubmed.ncbi.nlm.nih.gov/20602621","citation_count":27,"is_preprint":false},{"pmid":"20814155","id":"PMC_20814155","title":"Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.","date":"2010","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/20814155","citation_count":26,"is_preprint":false},{"pmid":"30012669","id":"PMC_30012669","title":"The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30012669","citation_count":26,"is_preprint":false},{"pmid":"23586031","id":"PMC_23586031","title":"Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/23586031","citation_count":26,"is_preprint":false},{"pmid":"15061384","id":"PMC_15061384","title":"Association between the CYP2C9 polymorphism and the drug metabolism phenotype.","date":"2004","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15061384","citation_count":25,"is_preprint":false},{"pmid":"23781667","id":"PMC_23781667","title":"Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.","date":"2012","source":"The Journal of the Association of Physicians of India","url":"https://pubmed.ncbi.nlm.nih.gov/23781667","citation_count":25,"is_preprint":false},{"pmid":"16749864","id":"PMC_16749864","title":"Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver.","date":"2006","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/16749864","citation_count":25,"is_preprint":false},{"pmid":"21167292","id":"PMC_21167292","title":"Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9).","date":"2010","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/21167292","citation_count":25,"is_preprint":false},{"pmid":"23996211","id":"PMC_23996211","title":"Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.","date":"2013","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23996211","citation_count":24,"is_preprint":false},{"pmid":"33262574","id":"PMC_33262574","title":"Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.","date":"2020","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33262574","citation_count":23,"is_preprint":false},{"pmid":"14583800","id":"PMC_14583800","title":"CYP2C9 gene and susceptibility to major depressive disorder.","date":"2003","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/14583800","citation_count":23,"is_preprint":false},{"pmid":"30030468","id":"PMC_30030468","title":"CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30030468","citation_count":22,"is_preprint":false},{"pmid":"19495518","id":"PMC_19495518","title":"CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia.","date":"2009","source":"Singapore medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19495518","citation_count":22,"is_preprint":false},{"pmid":"28687336","id":"PMC_28687336","title":"Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28687336","citation_count":22,"is_preprint":false},{"pmid":"25994031","id":"PMC_25994031","title":"Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59.","date":"2015","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25994031","citation_count":21,"is_preprint":false},{"pmid":"22863573","id":"PMC_22863573","title":"Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.","date":"2012","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22863573","citation_count":21,"is_preprint":false},{"pmid":"19381164","id":"PMC_19381164","title":"Prevalence of CYP2C9 polymorphisms in the south of Europe.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19381164","citation_count":21,"is_preprint":false},{"pmid":"17504998","id":"PMC_17504998","title":"CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17504998","citation_count":21,"is_preprint":false},{"pmid":"25157098","id":"PMC_25157098","title":"Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions.","date":"2014","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25157098","citation_count":21,"is_preprint":false},{"pmid":"24825094","id":"PMC_24825094","title":"Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy.","date":"2014","source":"Drug metabolism and drug interactions","url":"https://pubmed.ncbi.nlm.nih.gov/24825094","citation_count":20,"is_preprint":false},{"pmid":"33024249","id":"PMC_33024249","title":"Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.","date":"2020","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/33024249","citation_count":20,"is_preprint":false},{"pmid":"38103405","id":"PMC_38103405","title":"Heat stress induces ferroptosis of porcine Sertoli cells by enhancing CYP2C9-Ras- JNK axis.","date":"2023","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/38103405","citation_count":20,"is_preprint":false},{"pmid":"24430292","id":"PMC_24430292","title":"Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24430292","citation_count":20,"is_preprint":false},{"pmid":"32021384","id":"PMC_32021384","title":"The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children.","date":"2020","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32021384","citation_count":20,"is_preprint":false},{"pmid":"15349140","id":"PMC_15349140","title":"CYP2C9 genotype as a predictor of drug disposition in humans.","date":"2004","source":"Methods and findings in experimental and clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15349140","citation_count":19,"is_preprint":false},{"pmid":"37414240","id":"PMC_37414240","title":"Butyric acid inhibits oxidative stress and inflammation injury in calcium oxalate nephrolithiasis by targeting CYP2C9.","date":"2023","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/37414240","citation_count":19,"is_preprint":false},{"pmid":"19258521","id":"PMC_19258521","title":"CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.","date":"2009","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19258521","citation_count":19,"is_preprint":false},{"pmid":"21493749","id":"PMC_21493749","title":"The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression.","date":"2011","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21493749","citation_count":18,"is_preprint":false},{"pmid":"15618707","id":"PMC_15618707","title":"Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism.","date":"2002","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/15618707","citation_count":18,"is_preprint":false},{"pmid":"25760542","id":"PMC_25760542","title":"Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9.","date":"2014","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/25760542","citation_count":18,"is_preprint":false},{"pmid":"32868386","id":"PMC_32868386","title":"Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.","date":"2020","source":"European journal of hospital pharmacy : science and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32868386","citation_count":17,"is_preprint":false},{"pmid":"25560582","id":"PMC_25560582","title":"Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population.","date":"2014","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/25560582","citation_count":17,"is_preprint":false},{"pmid":"15288804","id":"PMC_15288804","title":"Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.","date":"2004","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/15288804","citation_count":17,"is_preprint":false},{"pmid":"28344492","id":"PMC_28344492","title":"CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.","date":"2016","source":"Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","url":"https://pubmed.ncbi.nlm.nih.gov/28344492","citation_count":17,"is_preprint":false},{"pmid":"32385545","id":"PMC_32385545","title":"Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.","date":"2020","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32385545","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58263,"output_tokens":6934,"usd":0.1394,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15877,"output_tokens":4685,"usd":0.098255,"stage2_stop_reason":"end_turn"},"total_usd":0.237655,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Transcriptional regulation of CYP2C9 by glucocorticoid receptor (GR) and constitutive androstane receptor (CAR): a glucocorticoid-responsive imperfect palindrome was identified at -1662/-1676 and a DR4 motif at -1803/-1818 in the CYP2C9 promoter. The DR4 motif is recognized and transactivated by CAR and pregnane X receptor (PXR). These elements were characterized by deletional analysis, co-transfection experiments, directed mutagenesis, gel shift assays, and response to specific antagonists (RU486, androstanol).\",\n      \"method\": \"Promoter deletion analysis, site-directed mutagenesis, co-transfection in hepatocytes, electrophoretic mobility shift assay (EMSA), specific receptor antagonists\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (EMSA, mutagenesis, reporter assays, antagonist treatments) in a single rigorous study with functional validation\",\n      \"pmids\": [\"11679585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Vitamin D receptor (VDR) binds and transactivates xenobiotic-responsive elements (ER6, DR3, DR4) in the CYP2C9 promoter previously identified as PXR/CAR targets, inducing CYP2C9 expression in primary human hepatocytes. VDR, PXR, and CAR compete for the same response elements in the CYP3A4/CYP2C9 promoter region.\",\n      \"method\": \"EMSA, co-transfection in HepG2 cells using wild-type and mutated oligonucleotides, reporter-gene assays in primary human hepatocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — EMSA plus mutagenesis plus co-transfection with multiple nuclear receptor expression vectors, confirmed in primary hepatocytes\",\n      \"pmids\": [\"11991950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Structural characterization of the CYP2C9 gene: nine coding exons spanning ~55 kb, with intron-exon organization similar to other CYP2C subfamily members. The 5'-upstream region contains TATA boxes, multiple glucocorticoid regulatory element consensus sequences, and a 15-base sequence with homology to a barbiturate-inducible element from P450BM-3 in Bacillus megaterium.\",\n      \"method\": \"Genomic cloning, restriction mapping, DNA sequencing of 2200 bp upstream region\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic sequencing and structural analysis, single lab, sequence-based functional inference\",\n      \"pmids\": [\"8333835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The CYP2C9*3 allele (Ile359Leu substitution) significantly reduces catalytic activity for all seven CYP2C9 substrates tested (S-warfarin, diclofenac, tolbutamide, phenytoin, piroxicam, and others). The Leu359 variant shows higher Km values for all substrates and reduced Vmax/Km (intrinsic clearance) ranging from 3.4- to 26.9-fold lower than wild-type. The substitution also decreases enantiomeric selectivity for phenytoin hydroxylation.\",\n      \"method\": \"Site-directed mutagenesis, cDNA expression in yeast, enzyme kinetic assays with seven substrates\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-directed mutagenesis combined with heterologous expression and kinetic analysis across seven substrates in a single rigorous study\",\n      \"pmids\": [\"10761997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CYP2C9*5 variant (Asp360Glu substitution) was identified in African Americans and expressed in insect cells. Comparative kinetic studies showed that Asp360Glu primarily increases Km (12-fold for S-warfarin 7-hydroxylation, 5-fold for diclofenac 4'-hydroxylation, 3-fold for lauric acid ω-1 hydroxylation) relative to wild-type CYP2C9*1, with in vitro intrinsic clearances 8–18% of CYP2C9*1 values.\",\n      \"method\": \"Single-strand conformational polymorphism, RFLP, baculovirus expression, purification from insect cells, comparative kinetic studies with three substrates\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purified recombinant protein, enzyme kinetics with multiple substrates, mutagenesis-equivalent allele expression system\",\n      \"pmids\": [\"11455026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CYP2C9*3 (homozygous) is associated with severely diminished clearance of S-warfarin. A patient homozygous for CYP2C9*3 who could tolerate only 0.5 mg/day warfarin showed a plasma S:R warfarin ratio of 3.9:1 (versus 0.50 ± 0.25 in controls), indicating selective impairment of S-warfarin metabolism. Urinary 7-hydroxywarfarin S:R ratio was normal (4:1), suggesting the defect is in clearance not in stereospecificity of available enzyme.\",\n      \"method\": \"PCR genotyping, restriction digest, chiral-phase HPLC measurement of plasma warfarin enantiomers and urinary metabolites\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single patient case with genotype confirmation and pharmacokinetic profiling, mechanistically informative but single subject\",\n      \"pmids\": [\"9352571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CYP2C9 and CYP3A4 physically interact via their hydrophobic N-terminal membrane-anchoring domains to form a heteromeric complex. This interaction inhibits CYP2C9-mediated metabolism (up to 80% inhibition of S-naproxen and S-flurbiprofen hydroxylation) without changing Km values, while CYP2C9 does not alter CYP3A4 testosterone metabolism. Truncation of either enzyme's N-terminus abolishes the inhibition. Increasing CPR concentrations relieves the inhibition.\",\n      \"method\": \"Reconstituted system incubations, truncated protein constructs, co-immunoprecipitation, varied CPR and cytochrome b5 concentrations\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — co-IP confirmed physical interaction, reconstituted system with domain truncation mutagenesis and activity assays, multiple orthogonal approaches\",\n      \"pmids\": [\"20215413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Modulation of CYP3A4 protein levels in human hepatocytes (HepatoPac long-term culture) inversely affects CYP2C9 activity: siRNA-mediated CYP3A4 knockdown (60% decrease) caused a 74% increase in CYP2C9 activity with no change in CYP2C9 mRNA, confirming post-translational protein-protein interaction between CYP3A4 and CYP2C9 in a physiological in vitro system.\",\n      \"method\": \"siRNA knockdown of CYP3A4 in HepatoPac long-term human hepatocyte culture, activity assays, mRNA and protein quantification\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockdown with functional readout in physiologically relevant system, single lab, confirms prior recombinant system finding\",\n      \"pmids\": [\"25157098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-130b directly targets the CYP2C9 3'-UTR and negatively regulates CYP2C9 activity. Transfection of miR-130b mimics in HepaRG cells significantly reduced CYP2C9 mRNA expression and decreased CYP2C9 enzyme activity by at least 30%. miR-130b also indirectly downregulates CYP2C9 by suppressing nuclear receptors CAR and FXRα. miR-130b levels are elevated in cholestasis and inflammation.\",\n      \"method\": \"miRNA mimic transfection in HepaRG cells, quantitative RT-PCR, LC-MS/MS cocktail P450 activity assay, 3'-UTR reporter gene assay\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter gene assay confirmed direct 3'-UTR targeting; functional activity reduction confirmed; single lab, two orthogonal methods\",\n      \"pmids\": [\"25802328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Estrogen receptor α (ERα) regulates CYP2C9 transcription through a functionally relevant ERE half-site at position -149/-145 in the CYP2C9 promoter. ERα binds this site (confirmed by EMSA and antibody supershift). ERα ligands differentially regulate CYP2C9 promoter activity: 4-hydroxytamoxifen and raloxifene upregulate, while 17α-ethinylestradiol suppresses, CYP2C9 promoter activity. Mutations in the ERE half-site abolish these effects. ChIP confirmed ERα association with the CYP2C9 promoter in cells.\",\n      \"method\": \"Luciferase reporter assay, site-directed mutagenesis of ERE half-site, EMSA with antibody supershift, chromatin immunoprecipitation (ChIP), primary hepatocyte experiments\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (reporter assay, mutagenesis, EMSA, supershift, ChIP, primary hepatocytes) in single rigorous study\",\n      \"pmids\": [\"21493749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PXR and CAR activate CYP2C9 gene expression in mouse liver through elements residing in the -2000 to -1000 bp region of the 5'-flanking sequence. Chemical inducers of PXR (rifampicin, PCN) and CAR (phenobarbital, TCPOBOP) significantly enhanced CYP2C9 promoter-driven luciferase expression when cotransfected with respective receptor expression vectors in vivo in mouse liver.\",\n      \"method\": \"Hydrodynamic delivery of reporter constructs to mouse liver, co-transfection with PXR or CAR expression vectors, luciferase reporter assay\",\n      \"journal\": \"Molecular pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo reporter assay with receptor co-expression, single lab, consistent with prior in vitro findings\",\n      \"pmids\": [\"16749864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Active-site mutagenesis at Phe100, Phe114, Leu208, and Phe476 in CYP2C9 reveals substrate-specific binding locations: F100L and F114W mutants show 4-5-fold increased catalytic efficiency for phenytoin, while F100W, F114L, F476L, and F476W mutants lose >90% phenytoin hydroxylation capacity. The pattern differs from S-warfarin and S-flurbiprofen, indicating these substrates occupy discrete locations within the active site. L208V and F114L mutants alter phenytoin's catalytic orientation. L208V uniquely enhances 6-hydroxylation of S-warfarin, providing experimental evidence for the F-G loop region in dictating substrate orientation.\",\n      \"method\": \"Site-directed mutagenesis of nine active-site positions, in vitro kinetic analysis, stereochemical analysis of hydroxylated metabolites\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic site-directed mutagenesis of nine positions with kinetic and stereochemical readouts, multiple substrates compared\",\n      \"pmids\": [\"19258521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Functional characterization of 32 CYP2C9 allelic variants expressed in COS-7 cells using S-warfarin as substrate revealed that CYP2C9.18, .21, .24, .26, .33, and .35 exhibit no enzyme activity, and 12 additional variants show significantly decreased activity, establishing the molecular basis for loss-of-function alleles.\",\n      \"method\": \"Transient expression of variant CYP2C9 proteins in COS-7 cells, S-warfarin hydroxylation kinetic assay\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — heterologous expression with functional enzyme assay, single lab, broad allele coverage\",\n      \"pmids\": [\"23752738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Massively parallel activity profiling of 6,142 CYP2C9 missense variants using a pooled yeast-based click-seq assay, combined with VAMP-seq abundance measurement in human cells for 6,370 variants, revealed that almost two-thirds of CYP2C9 variants show decreased activity and that protein abundance (stability) accounts for approximately half of the variation in CYP2C9 function.\",\n      \"method\": \"Click-seq pooled yeast activity assay, VAMP-seq (variant abundance by massively parallel sequencing) in human cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — massively parallel functional assay with orthogonal abundance measurement, thousands of variants assessed, rigorous quantitative framework\",\n      \"pmids\": [\"34314704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CYP2C9 metabolizes arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), and the CYP2C9*2 and CYP2C9*3 variants metabolize AA less efficiently than CYP2C9*1, primarily due to impaired reduction of these variant proteins by NADPH-P450 reductase. Expression of CYP2C9*2 or *3 in NSCLC cells produced lower EET levels, smaller/less vascularized tumors in mice, and reduced endothelial cell proliferation and migration, establishing a direct mechanistic link between CYP2C9 variant activity, EET biosynthesis, and tumor angiogenesis.\",\n      \"method\": \"In vitro kinetic assays with purified CYP2C9*1, *2, *3 proteins, NADPH-P450 reductase activity assays, NSCLC cell tumor xenograft mouse model, endothelial cell proliferation/migration assays, EET quantification\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — purified protein kinetics plus mechanistic in vivo tumor model plus cell biology assays, multiple orthogonal methods\",\n      \"pmids\": [\"30012669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CYP2C9 is the major enzyme responsible for losartan oxidation to the active carboxylic acid metabolite E-3174. CYP2C9 inhibitor sulfaphenazole blocked E-3174 formation at low losartan concentrations, while CYP3A4 inhibitor triacetyloleandomycin was effective only at high concentrations. CYP2C9.2 and CYP2C9.3 yeast-expressed variants showed significantly reduced losartan oxidation, primarily due to lower Vmax. CYP2C9*3 liver microsomes also showed lower oxidation rates.\",\n      \"method\": \"Human liver microsome incubations with selective inhibitors, yeast expression of CYP2C9 variants, HPLC metabolite analysis, kinetic analysis across 25 individual liver microsome samples with genotype correlation\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — selective inhibitor in microsomes plus heterologous expression of variants plus individual human liver microsome panel, multiple orthogonal approaches\",\n      \"pmids\": [\"11408373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CYP2C9*13 (Leu90Pro substitution) reduces lornoxicam 5'-hydroxylation in COS-7 cells (Vmax/Km 12% of wild-type CYP2C9*1; compared to 28% for CYP2C9*3). Protein levels of both CYP2C9*3 and *13 were lower than CYP2C9*1. In a clinical study, CYP2C9*1/*13 subjects showed 1.9-fold higher lornoxicam AUC and 44% lower oral clearance versus CYP2C9*1/*1.\",\n      \"method\": \"Transient transfection expression in COS-7 cells, enzyme kinetic assays, clinical pharmacokinetic study in CYP2C9*1/*13 heterozygotes\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinetics with heterologous expression corroborated by clinical PK data, single lab\",\n      \"pmids\": [\"15764711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dicloxacillin induces CYP2C9 expression and activity through activation of pregnane X receptor (PXR): dicloxacillin treatment in primary human hepatocytes produced a statistically significant dose-dependent increase in CYP2C9 expression and activity, and luciferase assays confirmed PXR activation as the mechanism.\",\n      \"method\": \"Open-label randomized clinical crossover study with tolbutamide as CYP2C9 probe, primary human hepatocyte gene expression and activity assays, luciferase-based nuclear receptor activation assay\",\n      \"journal\": \"British journal of clinical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clinical PK data plus mechanistic hepatocyte and reporter assay experiments, single lab\",\n      \"pmids\": [\"29105855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of CYP2C9 in complex with a TCA1 antitubercular thiophene analog revealed interaction patterns within the CYP2C9 active site; structure-guided optimization enabled generation of molecules with differential inhibitory activities against DprE1 and CYP2C9, providing structural basis for CYP2C9 inhibitor selectivity.\",\n      \"method\": \"X-ray crystallography of CYP2C9 in complex with TCA1 analog, structure-guided analog synthesis\",\n      \"journal\": \"Angewandte Chemie (International ed. in English)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure obtained but reported as secondary finding in a TB drug development paper; single study, no mutagenesis validation of binding mode\",\n      \"pmids\": [\"28815830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Heat stress increases CYP2C9 expression and EET production in porcine Sertoli cells, activating the Ras-JNK signaling pathway and inducing ferroptosis. Pharmacological inhibition of CYP2C9 with sulfaphenazole or siRNA knockdown of CYP2C9 reduced EET content, suppressed Ras-JNK activation, and alleviated ferroptosis. Ras inhibitor (salirasib) did not affect CYP2C9 expression or EET levels, indicating unidirectional signaling from CYP2C9-EETs to Ras-JNK.\",\n      \"method\": \"CYP2C9 siRNA knockdown, sulfaphenazole pharmacological inhibition, Ras inhibitor, flow cytometry (apoptosis/ROS), Western blotting (GPX4, TFR1, Ferritin, p-JNK), EET quantification in porcine Sertoli cells\",\n      \"journal\": \"Theriogenology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus pharmacological inhibition plus genetic pathway dissection (Ras inhibitor), single lab, porcine model\",\n      \"pmids\": [\"38103405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CYP2C9 promotes esophageal cancer cell proliferation through EET production. Selective pharmacological inhibition of CYP2C9 decreased tumor cell proliferation in esophageal cancer cell lines (KYSE30, PT1590, OE19), and this anti-proliferative effect was reversed by exogenous addition of 11,12-EET. CYP2C9 inhibition caused G0/G1 cell-cycle arrest.\",\n      \"method\": \"CYP2C9 inhibitor treatment of cancer cell lines, cell cycle analysis by FACS, EET rescue experiment\",\n      \"journal\": \"Prostaglandins & other lipid mediators\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with substrate rescue, cell cycle analysis, single lab\",\n      \"pmids\": [\"21167292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Active-site probing with hydantoin and barbiturate inhibitors established that CYP2C9 active site differs from CYP2C19 in stereochemical requirements: inhibitor stereochemistry does not markedly influence Ki toward CYP2C9, and log P adequately predicts inhibitor potency for CYP2C9, contrasting with CYP2C19 where stereochemistry is a major factor. All tested compounds were competitive inhibitors of CYP2C9.\",\n      \"method\": \"Synthesis of N-3 alkyl-substituted phenytoin, nirvanol, and barbiturate derivatives; Ki determination against recombinant CYP2C9 and CYP2C19; CoMFA modeling\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic SAR with recombinant enzyme kinetics and computational modeling, single lab\",\n      \"pmids\": [\"15288804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CYP2C9*3 (Ile359Leu) and CYP2C9*13 (Leu90Pro) variants reduce diclofenac 4'-hydroxylation in yeast-expressed enzyme. Both variants also alter the inhibitory potency of clinical drugs against diclofenac metabolism; in particular, CYP2C9*13 significantly weakens inhibition by sulfaphenazole, fluvastatin, fluvoxamine, and tranylcypromine, demonstrating that active-site substitutions alter drug-drug interaction profiles.\",\n      \"method\": \"Yeast expression of CYP2C9*1, *3, *13, kinetic analysis of diclofenac 4'-hydroxylation, Ki determination for nine inhibitors against each variant\",\n      \"journal\": \"Drug metabolism and pharmacokinetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — heterologous expression with systematic kinetics and inhibition profiling, single lab\",\n      \"pmids\": [\"20814155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP2C9 is a hepatic cytochrome P450 enzyme that catalyzes the hydroxylation of ~15% of clinically used drugs (including S-warfarin, phenytoin, diclofenac, tolbutamide, losartan, NSAIDs, and sulfonylureas) as well as endogenous arachidonic acid to epoxyeicosatrienoic acids (EETs); its active site accommodates substrates through substrate-specific binding subsites defined by residues Phe100, Phe114, Leu208, and Phe476; common coding variants CYP2C9*2 (Arg144Cys), *3 (Ile359Leu), *5 (Asp360Glu), and *13 (Leu90Pro) reduce intrinsic clearance primarily by increasing Km and, for *3, by impairing reduction by NADPH-P450 reductase; transcription is induced via GR, CAR, PXR, and VDR acting on promoter elements at -1662/-1676 (GRE palindrome), -1803/-1818 (DR4/CAR-PXR element), and by ERα through an ERE half-site at -149/-145, while miR-130b directly suppresses CYP2C9 via its 3'-UTR; CYP2C9 forms a physical heteromeric complex with CYP3A4 through hydrophobic N-terminal membrane anchors, resulting in inhibition of CYP2C9 activity; and CYP2C9-derived EETs promote tumor cell proliferation and angiogenesis through a Ras-JNK signaling axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP2C9 is a hepatic cytochrome P450 monooxygenase that hydroxylates a broad range of clinical drugs—including S-warfarin, diclofenac, tolbutamide, phenytoin, losartan, and NSAIDs—as well as endogenous arachidonic acid to epoxyeicosatrienoic acids (EETs) [#3, #14, #15]. Substrate handling is governed by discrete active-site subsites: systematic mutagenesis at Phe100, Phe114, Leu208, and Phe476 shows that distinct substrates occupy different binding locations, with the F-G loop region dictating substrate orientation, so that single substitutions can selectively enhance or abolish turnover of one substrate without affecting others [#11]. Common coding variants degrade function by mechanistically distinct routes: CYP2C9*3 (Ile359Leu) and *5 (Asp360Glu) raise Km and lower intrinsic clearance across multiple substrates [#3, #4], *13 (Leu90Pro) and *3 reduce protein abundance [#16], and *2/*3 specifically impair reduction by NADPH-P450 reductase [#14]; massively parallel variant profiling generalizes this, showing that nearly two-thirds of missense variants reduce activity and that protein stability accounts for roughly half of functional variation [#13]. Allelic loss-of-function carries direct clinical consequence, as homozygous *3 produces severely diminished S-warfarin clearance [#5]. Transcription is controlled by a nuclear-receptor regulatory network: GR, CAR, PXR, and VDR act through promoter elements including a glucocorticoid palindrome at -1662/-1676 and a DR4 motif at -1803/-1818, for which these receptors compete [#0, #1, #10], ERα regulates the gene through an ERE half-site at -149/-145 in a ligand-dependent manner [#9], and miR-130b suppresses CYP2C9 both directly via the 3'-UTR and indirectly by repressing CAR and FXRα [#8]. Post-translationally, CYP2C9 forms a heteromeric complex with CYP3A4 via their N-terminal membrane anchors, which inhibits CYP2C9 activity in a manner relieved by increasing reductase [#6, #7]. Beyond xenobiotic metabolism, CYP2C9-derived EETs drive proliferation and angiogenesis in tumor cells through a Ras-JNK signaling axis [#14, #20, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the genomic architecture and regulatory landscape of CYP2C9, framing where transcriptional control would later be mapped.\",\n      \"evidence\": \"Genomic cloning and sequencing of the gene and 2200 bp upstream region\",\n      \"pmids\": [\"8333835\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Regulatory elements inferred from sequence homology, not functionally validated\", \"No protein-level functional data\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected a defined CYP2C9 genotype to a clinical metabolic phenotype, showing homozygous *3 selectively impairs S-warfarin clearance.\",\n      \"evidence\": \"PCR genotyping and chiral-phase HPLC of warfarin enantiomers in a homozygous *3 patient\",\n      \"pmids\": [\"9352571\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-subject case\", \"Does not isolate the enzymatic mechanism of impairment\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the enzymatic basis of the *3 loss-of-function allele as a broad increase in Km/decrease in intrinsic clearance across substrates.\",\n      \"evidence\": \"Site-directed mutagenesis, yeast cDNA expression, kinetics with seven substrates\",\n      \"pmids\": [\"10761997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address protein abundance contribution\", \"Yeast system may not reflect hepatic reductase coupling\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the nuclear-receptor promoter elements (GR palindrome, DR4 for CAR/PXR) controlling CYP2C9 induction, defining the xenobiotic transcriptional axis.\",\n      \"evidence\": \"Promoter deletion, mutagenesis, EMSA, co-transfection in hepatocytes with antagonists\",\n      \"pmids\": [\"11679585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological inducers not enumerated\", \"Cross-talk between receptors not resolved here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Characterized the *5 variant as another Km-increasing loss-of-function allele and established CYP2C9 as the major losartan-activating enzyme.\",\n      \"evidence\": \"Baculovirus expression and purification, kinetics; microsome inhibitor studies and variant expression for losartan\",\n      \"pmids\": [\"11455026\", \"11408373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate-specific magnitude of *5 effect varies\", \"Reductase coupling not measured\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended the regulatory network by showing VDR competes with PXR/CAR for the same response elements, integrating vitamin D signaling into CYP2C9 control.\",\n      \"evidence\": \"EMSA, mutated oligonucleotides, reporter assays in HepG2 and primary hepatocytes\",\n      \"pmids\": [\"11991950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of VDR induction in vivo not established\", \"Competition dynamics quantitatively undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Confirmed PXR/CAR-driven induction operates in intact liver, validating the in vitro promoter model in vivo.\",\n      \"evidence\": \"Hydrodynamic reporter delivery to mouse liver with receptor co-expression and chemical inducers\",\n      \"pmids\": [\"16749864\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mouse liver context, not human\", \"Precise element usage not mapped in vivo\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved the active site into substrate-specific binding subsites, explaining how single residues differentially govern turnover of distinct drugs.\",\n      \"evidence\": \"Site-directed mutagenesis of nine active-site positions with kinetic and stereochemical readouts\",\n      \"pmids\": [\"19258521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure for most substrates\", \"Does not address dynamics of substrate entry\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed a post-translational regulatory mechanism: CYP2C9 forms an inhibitory N-terminal-anchored heterocomplex with CYP3A4.\",\n      \"evidence\": \"Reconstituted system, N-terminal truncation constructs, co-IP, varied CPR/b5\",\n      \"pmids\": [\"20215413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the complex undefined\", \"Structural basis of the interface not solved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked CYP2C9-derived EETs to cancer cell proliferation, opening an endogenous signaling role beyond drug metabolism.\",\n      \"evidence\": \"Pharmacological CYP2C9 inhibition in esophageal cancer lines with cell-cycle analysis and 11,12-EET rescue\",\n      \"pmids\": [\"21167292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor selectivity not genetically confirmed here\", \"Downstream signaling not dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Added estrogen-receptor control through an ERE half-site, with ligand-dependent up- or down-regulation.\",\n      \"evidence\": \"Reporter assays, ERE mutagenesis, EMSA/supershift, ChIP, primary hepatocytes\",\n      \"pmids\": [\"21493749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological estrogen effect on hepatic CYP2C9 in vivo not quantified\", \"Interaction with xenobiotic receptors unexplored\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Broadened the catalog of loss-of-function alleles, identifying multiple null and reduced-activity variants on S-warfarin.\",\n      \"evidence\": \"Transient expression of 32 variants in COS-7 with S-warfarin kinetics\",\n      \"pmids\": [\"23752738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single substrate tested\", \"Protein abundance vs catalytic effects not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated the CYP3A4-CYP2C9 interaction operates in physiological hepatocytes, with CYP3A4 levels inversely tuning CYP2C9 activity.\",\n      \"evidence\": \"CYP3A4 siRNA knockdown in HepatoPac culture with activity, mRNA, and protein readouts\",\n      \"pmids\": [\"25157098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous regulators of CYP3A4 abundance not addressed\", \"Quantitative interplay across genotypes unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified miR-130b as a direct and indirect post-transcriptional repressor of CYP2C9, linking expression to cholestasis and inflammation.\",\n      \"evidence\": \"miRNA mimic transfection in HepaRG, 3'-UTR reporter, qRT-PCR, LC-MS/MS activity\",\n      \"pmids\": [\"25802328\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo regulation by miR-130b not demonstrated\", \"Relative weight of direct vs indirect (CAR/FXRα) effects unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established the EET-tumor angiogenesis axis mechanistically and showed reduced-function variants impair it via defective reductase coupling.\",\n      \"evidence\": \"Purified protein kinetics, reductase assays, NSCLC xenografts, endothelial assays, EET quantification\",\n      \"pmids\": [\"30012669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability across tumor types not shown\", \"Contribution of EETs vs other CYP2C9 products not isolated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided a genome-scale functional map showing protein stability accounts for about half of CYP2C9 functional variation.\",\n      \"evidence\": \"Click-seq pooled yeast activity assay plus VAMP-seq abundance in human cells across thousands of variants\",\n      \"pmids\": [\"34314704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single substrate context for activity assay\", \"Clinical translation of variant scores not validated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Generalized the CYP2C9-EET-Ras-JNK signaling axis to stress-induced ferroptosis, defining it as unidirectional from enzyme to signaling.\",\n      \"evidence\": \"siRNA, sulfaphenazole, Ras inhibitor epistasis, ferroptosis markers in porcine Sertoli cells\",\n      \"pmids\": [\"38103405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Porcine model; human relevance untested\", \"Molecular link between EETs and Ras activation not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How transcriptional, post-transcriptional (miR-130b), and post-translational (CYP3A4 complex) layers are jointly coordinated to set hepatic CYP2C9 activity in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated in vivo model combining the regulatory layers\", \"Structural basis of the CYP3A4 interface unsolved\", \"Relative contribution of each layer to interindividual drug-response variability unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [3, 4, 14, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 11, 14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [14, 20, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [3, 15, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 4]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 9, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 20, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CYP3A4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}